Fig. 4
Immune clusters and clinicopathological features. a, b Average percentage of ER-positive and ER-negative samples (a) or PAM50 subtypes (b) of 15 cohorts across the clusters. Cluster A is enriched for ER-positive, Luminal A, Luminal B samples while a significantly higher percentage of ER-negative, Basal-like, Her2-enriched samples was found in Cluster C (high infiltration). Asterisk (*) denote t test p value < 0.0001. Error bars represent standard error to the mean. c Prosigna Breast Cancer ROR scores for the OSLO2-EMIT0 cohort were obtained from the NanoString nCounter Dx Analysis System using FFPE breast tumor tissue. Boxplots represent the average Prosigna ROR scores in the immune clusters. Kruskal–Wallis test p value is denoted. d Calculated ROR scores following the method of Parker et al.3 are compared to immune clusters using boxplots in the METABRIC cohort. Kruskal–Wallis test p values is shown. e From eight breast cancer cohorts, in which the pathological complete response (pCR) was assessed after administration of neoadjuvant chemotherapy, we calculated the percentage of responders in each cluster. Boxplots show the distribution of the percentage of responders in each immune cluster. Kruskal–Wallis test p value is denoted. The line within each box represents the median. Upper and lower edges of each box represent 75th and 25th percentiles, respectively. The whiskers represent the lowest datum still within [1.5 × (75th − 25th percentile)] of the lower quartile and the highest datum still within [1.5 × (75th − 25th percentile)] of the upper quartile.
